Cancer care is not as appropriate as one imagines in a modern and a developed country as America. The state of the cancer is not at all good. America receives a very high number of patients when it comes to cancer. The number is increasing day by day and the workforce is not very much efficient in getting the best out of it. Immunotherapy has risen as the fourth pillar of treatment beyond the traditional triumvirate of chemotherapy, surgery, and radiation. Population density is a key driver not only of patient location but also of the critical concentration of physician-scientists and research staff necessary to operationalize studies, particularly in their earlier phases, and to ensure inclusion of diverse populations.
1,500 cancer centers in the United States, only 51 as of this writing have received designation as comprehensive by the National Cancer Institute. As the Levit et al reported, approximately 14% of Americans reside > 180 minutes travel time from an NCI-designated cancer center or satellite facility, which compounds both the inconvenience and the expense associated with onsite visits and thus disincentivizes enrollment in studies with multiple obligate touch points, each with its own monetary and opportunity costs.
So all over there is a need to improve the condition of cancer care in America.
https://ascopubs.org/doi/full/10.1200/OP.20.00585
